Insiders Orphazyme A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 15:01:50 08/05/2024 BST			5-day change	1st Jan Change
1,010 ^DKK	-7.76%		+2.20%	-24.06%

03-27	Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-04	FDA Extends Review of Zevra's Arimoclomol by Three Months	DJ

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CEO	30/05/23	CI
Orphazyme A/S Announces Board Changes	17/05/23	CI
Orphazyme A/S Announces Board Appointment	29/06/22	CI
Orphazyme A/S Announces Executive Changes	23/05/22	CI
Orphazyme CFO Anders Vadsholt Takes on CEO Role a Month Early	28/02/22	MT
Orphazyme A/S Elects Andrew Mercieca as Member of the Board of Directors	15/02/22	CI
Orphazyme A/S : Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO - Form 6-K	31/01/22	PU
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO	31/01/22	GL
Orphazyme A/S Announces CEO Changes	31/01/22	CI
Centogene CEO Andrin Oswald to Take Medical Leave; Interim CEO Named	20/12/21	MT
Orphazyme Announces Changes to the Board of Directors	09/12/21	CI
Orphazyme A/S Announces Board Resignation	28/06/21	CI
Orphazyme A/S Announces Appointment of Stephanie Okey as New Member to the Board of Directors	25/03/21	CI
Orphazyme Appoints Christophe Bourdon as Chief Executive Officer, Effective April 1, 2021	25/03/21	CI
Orphazyme A/S Appoints Christophe Bourdon as Chief Executive Officer, Effective on April 1, 2021	01/03/21	CI
Orphazyme A/S Announces Executive Changes	10/12/20	CI
Orphazyme A/S Announces Appointments	07/12/20	CI
Orphazyme A/S Elects Carrolee Barlow as Board of Director	21/09/20	CI
Orphazyme A/S Announces Executive Changes	28/08/19	CI
Orphazyme A/S Announces Management Changes	15/07/19	CI

No results for this search